Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by u2bobon Dec 13, 2018 8:15am
81 Views
Post# 29108123

Something Up ?

Something Up ?

 

Diagnos closes $332,500 financing at a nickel

 

2018-12-12 17:56 ET - News Release

 

Mr. Andre Larente reports

Diagnos Inc. has closed a private placement of 6.65 million units issued at five cents per unit for gross proceeds of $332,500.

Each unit consists of:

 

  • One common share;

 

 

  • One stock warrant, entitling the holder to purchase one share per warrant at a price of six cents per share, for a period of 18 months ending June 12, 2020.

 

The proceeds will be used mainly to finance sales and marketing as well as administrative expenses.

Shares issued as part of the private placement as well as the underlying shares to be issued upon exercise of the warrants are subject to a statutory four-month hold period ending April 12, 2019.

The private placement is subject to final receipt of all required approvals, including the final approval of the TSX Venture Exchange, as well as the execution of formal documentation.

All moneys quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Bullboard Posts